Sign inJoin waitlistJoin the waitlist

Liza Villaruz

Director, Center for Ultrasound Molecular Imaging and Therapeutics · UPMC Medical Education

Credentials: · · ·

History

Center for Ultrasound Molecular Imaging and Therapeutics · UPMC Medical Education
Present
UPMC Medical Education
Present

Medical Oncology
UPMC Medical Education
2007–2010
Internal Medicine
2005–2008
University of Maryland School of Medicine
2001–2005

Research

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
New England Journal of Medicine · 2017 · 2,096 citations
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Nature Medicine · 2020 · 325 citations
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Journal of Thoracic Oncology · 2022 · 276 citations

MS
Mark Socinski
31 papers
Jared Weiss
13 papers
Ross Camidge
11 papers
Jorge Nieva
7 papers
SD
Sanja Dacic
7 papers
Thomas Stinchcombe
7 papers
Timothy Burns
7 papers
JR
John Rhee
6 papers
Jonathan Dowell
6 papers
Stephen Liu
6 papers
Tejas Patil
6 papers
Wade Iams
6 papers

Grants

NCI ETCTN Pittsburgh Cancer Consortium (PCC)
National Cancer Institute · UM1
Contact PI · $3.1M · University of Pittsburgh at Pittsburgh
2014–2027

Clinical trials

Impact of Circadian Rhythm on Immunotherapy
Principal investigator · Recruiting · Phase 2
Liza Villaruz, MD
2025–2030
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
Principal investigator · Terminated · Phase 2
Liza Villaruz, MD
2023–2025
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2021–2027
Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2021–2027